Scientists from the United Kingdom may have identified several more environmental causes for cancer after evaluating the genetic data of over 12,000 cancer patients from National Health Service files.
Research published in Trends in Genetics by Dr. Leslie Lyons, Gilbreath-McLorn endowed professor of comparative medicine at the University of Missouri College of Veterinary Medicine, could be instrumental to the development of personalized therapeutics for both two-legged and four-legged patients.
Shares of uniQure NV climbed after the company announced the clinical hold on its hemophilia B gene therapy was lifted by the U.S. Food and Drug Administration.
U.S-based cancer testing startup Grail Inc., a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) with the U.S. Securities and Exchange Commission.
Researchers with Scripps Research and other institutions around the globe published a study in the journal Nature Medicine debunking the theory that the novel coronavirus that causes COVID-19 is manmade after an analysis of the genome sequence of SARS-CoV-2.
What if you could detect cancer just as it is getting started? New research published in the journal Nature just might give medicine the tools to do just that.
In this webinar, Dr. Benjamin Darbro and Alyssa Hahn will discuss how their organization is using Natural Language Processing to transform unstructured source data into clinical and research decision support insights.
Working in the rare disease space has never been more rewarding than it is today. Technology is turning what was once thought to be impossible into actual, tangible realities for physicians, patients, and families. There are many exciting advancements happening now – in real time – and even more on the horizon that demand our attention and advocacy to help bring them to light.
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and KingMed Diagnostics, a laboratory services leader in China, announced that they have entered into a strategic partnership for the PGDx elioTM tissue complete assay.
When consumers have their genome tested by services such as 23andMe and Ancestry.com, the companies hold the rights to the genetic information, which they often sell to biopharmaceutical companies. Nebula Genomics is taking a different approach.